INOVIQ update

18th November 2024

Next-generation cancer diagnostics and therapeutics

BELL POTTER

Healthcare Conference 2024

Important notice and disclaimer

This presentation has been prepared by INOVIQ Limited ("INOVIQ" or the "Company") based on information available to it as at the date of this presentation. This presentation contains general and background information about the Company's activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision and does not contain all information about the Company's assets and liabilities, financial position and performance, profits and losses, prospects, and the rights and liabilities attaching to the Company's securities necessary to make an investment decision. The information in this presentation should be read in conjunction with the Company's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), available at www.asx.com.au. The information in this presentation is based on the Company's own information and estimates and has not been independently verified. The Company is not responsible for providing updated information and assumes no responsibility to do so. Any investment in the Company should be considered speculative and there is no guarantee that they will make a return on capital invested, that dividends would be paid, or that there will be an increase in the value of the investment in the future.

This Presentation may contain certain "forward-looking statements" that are based on management's beliefs, assumptions and expectations and on information currently available to management. The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings, financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including INOVIQ or any of its advisers). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this Presentation will actually occur. Actual operations, results, performance, targets or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based.

Nothing contained in this Presentation constitutes investment, legal, tax or other advice. This Presentation does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of the Company's prospects.

You should note that any past performance is given for illustrative purposes only and should not be relied on as (and is not) an indication of the Company's views on its future financial performance or condition. Past performance, including past share price performance, of INOVIQ cannot be relied on as an indicator of (and provides no guidance as to) future performance including future share price performance.

INOVIQ Overview| Next generation diagnostics and therapeutics

Exosome powered

Next-gen exosome solutions for earlier detection and treatment of cancer

Disruptive technology

Proprietary exosome and SubB2M technologies underpinning pipeline

Products in market

Exosome research tools and bladder cancer test in-market and generating revenues

Deep pipeline

Differentiated, multi-stage exosome research tool, diagnostic and therapeutic pipeline for cancer

Excellent clinical data

Data showing superior exosome isolation, accurate cancer detection and in vitro cancer killing activity

Partnering for growth

Commercialization via partnering with distributors, clinical laboratories and pharma

- Biotech pioneering **next-generation cancer diagnostics and therapeutics** to enhance patient outcomes
- **Expertise** in exosome science, diagnostics, drug development & commercialization
- Leader in high-growth **exosome market** that is expected to reach US $6.8 billion by 2032
- Product portfolio includes:
  - ✓ 2 in-market products for **exosome research** and bladder cancer detection
  - ✓ 3 in-development glycovariant and **exosome diagnostics** for detection and monitoring of breast and ovarian cancers
  - ✓ early-stage CAR-**exosome therapeutic** program for solid tumours

INOVIQ

Board & Management| Corporate, scientific and commercial expertise

DAVID WILLIAMS
Non-Executive Chairman

Experienced biotechnology director and investment banker with extensive strategic, corporate and financial markets experience.

Currently Chairman PolyNovo Ltd, Chairman of RMA Global Ltd and Managing Director of corporate advisory firm Kidder Williams Ltd.

Previously Chairman and major shareholder Medical Developments International Ltd. Major shareholder Healthily Pty Ltd.

DR GEOFF CUMMING
Non-Executive Director

Healthcare and biotechnology director with extensive diagnostics industry experience.

Currently NED AnteoTech Ltd.

Previously Managing Director Roche Diagnostic Systems (Oceania), MD/CEO Biosceptre international Ltd and MD/CEO of Anteo Diagnostics Ltd.

MAX JOHNSTON
Non-Executive Director

Healthcare industry director and international business leader with extensive experience across medtech, pharmaceuticals, consumer healthcare and consumer goods.

Currently NED Neurotech International. Previously President and CEO of Johnson & Johnson Pacific, Chairman of AusCann Ltd, NED of PolyNovo Ltd, Medical Developments International Ltd, Tissue Repair Ltd and CannPal Animal Therapeutics Ltd.

PHILIP POWELL
Non-Executive Director

Healthcare industry director and chartered accountant with extensive investment banking experience specialising in capital raisings, IPOs, mergers and acquisitions and other transactions across pharma, food and agriculture.

Previously at OAMPS Ltd and Arthur Andersen, and NED at RMA Global Ltd, Polynovo Ltd and Medical Developments International Ltd.

MARY HARNEY
Non-Executive Director

Experienced Non-Executive Director, Chief Executive and consutant with a deep understanding of applied life science research, biopharmaceutical regulatory affairs and commercialisation.

Currently Chair of Microbio Pty Ltd and Oncology One Pty Ltd. Previously Chair of Race Oncology, CEO of RACS, CEO Gardiner Research Foundation and COO/Director of Office of Cancer Research at PeterMac.

DR LEEARNE HINCH BVMS MBA
Chief Executive Officer

Biotechnology CEO with a proven track record in corporate strategy, capital raising, product development, business development and partnering across diagnostics, medical devices, therapeutics and animal health.

Past leadership and consulting roles in ASX-listed biotechnology, multinational and private companies including Eustralis Pharmaceuticals, HealthLinx, OBJ, Holista Colltech, Chemeq, Virbac and Mars.

DR GREG RICE PhD MHA
Chief Scientific Officer

Internationally recognised, award-winning scientist with over 35 years' experience and a successful track record in oncology research, exosome science, biomarker discovery, and diagnostics development.

Previous leadership roles in academia and industry including at The University of Queensland Centre for Clinical Research, Baker Heart Institute, University of Melbourne, Monash University and HealthLinx.

MARK EDWARDS BAcc CA
CFO & Company Secretary

Experienced finance executive with expertise in financial leadership and management, corporate governance, investor relations and corporate transactions.

Previous senior roles in ASX listed pharmaceutical, medical device and healthcare companies, including Medical Developments International and Cogstate.

Core Technologies| Research tools, diagnostics and therapeutics

Strategic Focus

Next-generation exosome diagnostics and therapeutics for cancer

Core Technologies

Exosome Platform

NETs™ immunoaffinity, magnetic bead-based EV isolation

EXO-ACE™ affinity chromatography large-scale EV isolation

SubB2M Technology

Proprietary neu5Gc probe for improved cancer detection

Pipeline

Research Tools

EXO-NET® exosome isolation tools for biomarker discovery and diagnostics

US$661m[1]

Diagnostics

Exosome tests for screening, liquid biopsies & companion diagnostics

SubB2M tests for cancer monitoring

US$6.1b[2]

Therapeutics

Exosome therapeutics to target and kill solid tumours

US$55.3b[3]

1. Global Exosome Research Market (2021 - 2026) (researchandmarkets.com); 2. Breast Cancer Diagnostics Market Size & Share Report 2030 (grandviewresearch.com); 3. Ovarian Cancer Diagnostics Market Size, Share 2019 to 2026 (acumenresearchandconsulting.com) 4. Breast Cancer Therapeutics Market Growth, Trends & Dynamics, 2027 (fortunebusinessinsights.com)

INOVIQ

Exosome Platform



INOVIQ

Exosomes| Significant diagnostic and therapeutic potential



- **Exosomes** are small vesicles released by cells that perform key roles in intercellular communication, immune regulation and disease progression
  - Exosomes carry molecular cargo (**DNA, RNA, proteins and lipids**) that act as cell messengers or biomarkers of disease
  - Exosome biomarkers can be used to develop advanced **diagnostics**
  - Exosomes can be loaded with drugs (small molecules, RNA, other) and engineered for targeted delivery of **therapeutics**
- Significant investment by large pharma and diagnostic companies in exosome products for Oncology, Neurodegenerative, Infectious & Inflammatory diseases
- **INOVIQ's next-gen exosome platform** enables multiple applications

Research	Diagnostics	Therapeutics
Exosome isolation tools for biomarker discovery & validation	Exosome tests for screening, therapeutic selection and monitoring	Engineered exosomes to target and treat cancer

Exosomes = small Extracellular Vesicles (EV)

INOVIQ

EXO-NET®| Pan-exosome isolation product in-market and generating revenue

Best-in-class **EXO-NET pan-exosome capture** tool (research use only) in-market and generating revenue

Enables **biomarker discovery and diagnostic development** for screening, liquid biopsies and companion diagnostics

Offers **speed, efficiency and scalability** advantages with over 500 samples/day[1]

Data published validating EXO-NET utility in cancer, neurodegenerative, periodontitis, placental and inflammatory diseases[2,3,4]

Distribution partnership with Promega Corporation to market and sell EXO-NET to Academic, Biotech/Pharma & Clinical Lab/Hospital customers worldwide



*"[INOVIQ's] new HT exosome isolation and biomarker analysis solution **solves an industry challenge** needed to commercialise exosome-based diagnostics."*

Tom Livelli, Vice President, Promega

1. Appendix: Competitor comparison includes Biotechne, FUJIFILM Wako, Thermo Fisher Scientific, QIAGEN & others;
2. ISEV (ASX: 19/5/23), ANZSEV (ASX: 10/11/23) and AMP (12/11/23); 3. Immunoaffinity-enriched salivary small extracellular vesicles in periodontitis (oaepublish.com); 4. High throughput Surface Epitope Immunoaffinity Isolation of EVs (oup.com)

Promega INOVIQ

NEURO-NET™ | Brain-derived exosome isolation now validated & available

Custom **NEURO-NET exosome capture** tool for isolation of brain-derived exosomes

Designed using **proprietary antibody combination** that isolates exosomes secreted from brain cells (neurons, microglia, oligodendrocytes & astrocytes)

Exosomes cross the "*blood-brain barrier*" and provide a "*fingerprint*" of the health or disease status of the brain for *brain cancer, neuropsychiatric disorders and neurodegenerative diseases*

NEURO-NET analytical and clinical validation studies in Alzheimer's Disease (AD)[1] **and Parkinson's Disease (PD)**[2] show:

- ✓ NEURO-NET isolates and enriches exosomes from blood that contain proteins expressed by brain cells
- ✓ NEURO-NET was superior to other methods tested for isolating brain-derived exosomes from blood
- ✓ Identified known AD & PD biomarkers not detected by other exosome isolation methods
- ✓ Identified >200 proteins differentially expressed between AD & healthy patients
- ✓ Validated 47 protein biomarkers providing robust discrimination between AD & healthy

NEURO-NET expands INOVIQ's exosome capabilities to develop new diagnostics for neurological conditions. Brain-derived exosomes hold enormous potential for diagnosis and treatment of neurological diseases.

NEURO-NET identifies differently-expressed proteins from Alzheimer's Disease plasma

>200 differentially expressed proteins
47 unique to Alzheimer's Disease



1. NEURO-NET validation studies in Alzheimer's Disease (ASX: 12/6/24) and 2. Parkinson's Disease (ASX: 20/8/24)

EXO-NET| Multiple publications, posters and presentations

High-throughput surface epitope immunoaffinity isolation of extracellular vesicles and downstream analysis

Ramin Khanabdali ✉, Michelle Mandrekar, Rick Grygiel, Phuoc-An Vo, Carlos Palma, Sara Nikseresht, Siena Barton, Mozhgan Shojaee, Sadman Bhuiyan, Kartini Asari ... Show more

Biology Methods and Protocols, Volume 9, Issue 1, 2024, bpae
https://doi.org/10.1093/biomethods/bpae032
Published: 17 May 2024 **Article history**

PDF | Split View | Cite | Permissions

Abstract

Extracellular vesicles (EVs), including exosomes, have diagnostic and therapeutic applications. The lack of sta efficient and high-throughput isolation and analysis o limited their widespread use in clinical practice. Surfac immunoaffinity (SEI) isolation utilizes affinity ligands aptamers, or lectins, that target specific surface protei Paramagnetic bead-SEI isolation represents a fit-for-p reproducible, high-throughput isolation of EVs from b analysis of RNA, protein, and lipid biomarkers that is c laboratory workflows. This study evaluates a new SEI is enriching subpopulations of EVs. EVs were isolated from human plasma using a bead-based SEI method designed for on-bead and downstream analysis of EV-associated RNA and protein biomarkers. Western blot analysis confirmed the presence of EV markers in the captured nanoparticles. Mass spectrometry analysis of the SEI lysate identified over 1500 proteins, with the top 100 including known EV-associated proteins. microRNA (miRNA) sequencing followed by RT-qPCR analysis identified EV-associated miRNA transcripts. Using SEI, EVs were isolated using automated high-throughput particle moving instruments, demonstrating equal or higher protein and miRNA yield and recovery compared to manual processing. SEI is a rapid, efficient, and high-throughput method for isolating enriched populations of EVs; effectively reducing contamination and enabling the isolation of a specific subpopulation of EVs. In this study, high-throughput EV isolation and RNA extraction have been successfully implemented. This technology holds great promise for advancing the field of EV research and facilitating their application for biomarker discovery and clinical research.

Immunoaffinity-enriched salivary small extracellular vesicles in periodontitis

Languages

Views: 909 | Downloads: 216 | Cited: Crossref 3

Chun Liu[1], Chaminda Jayampath Seneviratne[1], ... Pingping Han[1] + Show Authors

Extracell Vesicles Circ Nucleic Acids 2023;4:698-712.
10.20517/evcna.2023.48 | © The Author(s) 2023.
Author Information | Article Notes | Cite This Article

Abstract

Aim: Saliva extracellular vesicles (EVs) serve as a significant reservoir of biom EVs of both host- and bacterial- origin. Identifying suitable EVs for disease diag effective isolation methods. The objectives of this research were: (1) to evaluat different methods: size exclusion chromatography (SEC) and bead-based immu inflammatory cytokines in EXO-NET-enriched EVs, comparing individuals with

Methods: Whole unstimulated saliva samples were collected from 12 periodon periodontitis patients using SEC (referred to as SEC-EVs) and EXO-NET (referr markers, and bacterial pathogens expression were compared. Subsequently, the IL-10) in EXO-NET EVs were measured for non-periodontitis and periodontitis

Results: EXO-NET EVs contained more EV-specific protein and substantially h DNA was detected compared to that in SEC-EVs. Additionally, EXO-NET EVs fr decreased IL-10, compared to those from non-periodontitis patients.

Conclusion: The findings suggest that immunoaffinity capture (EXO-NET) is a host EVs with reduced bacterial DNA detection compared to SEC. Furthermore as biomarkers for periodontitis, demonstrated by an increased expression of pr





INOVIQ

EXO-NET® | Fast, efficient and specific EV isolation technology

EXO-NET technology

Proprietary immunoaffinity, magnetic bead-based EV capture system for fast, efficient and specific isolation of EVs

Speed

Easy and convenient workflow with **15 minute** EV capture

High Yield

High yield and capture of EVs from **multiple** biofluids including plasma, serum, saliva and urine

Specificity

Customizable to isolate specific subpopulations of EVs from different cell types & tissues (pan, cancer, brain)

Purity

High enrichment of EV RNA and protein markers with reduced co-isolation of contaminants

High-Throughput

Suitable for **manual, automated and high-throughput** processing

Downstream Compatibility

Compatible for use with most downstream applications (qPCR, RNASeq, FACs, Mass Spec, ELISA)

INOVIQ

Exosome Diagnostics| Academic collaboration validating EXO-NET

Collaboration with UQ to develop blood-based exosomal screening test for ovarian cancer[1]

- **UQ[1] OCRF-7 test** developed in a retrospective case-control study achieving over **90% accuracy** for detection of stage I / II ovarian cancer
- OCRF-7 biomarker algorithm was developed in a 465-sample discovery set[2]
- Exosome isolation initially performed using SEC (not compatible with pathology lab workflow) and **successfully transferred to EXO-NET**
- **Biomarker validation study** underway using EXO-NET exosome isolation on 500-sample independent set[3]
- Meets **critical need** for early detection of ovarian cancer to improve treatment options, women's health outcomes and help save lives
- INOVIQ has the **exclusive option to license** the development and commercialisation rights



1. The University of Queensland (UQ) (ASX: 1/4/22); 2. Research supported by an Ovarian Cancer Research Foundation (OCRF) grant; 3. Research supported by $2.7m Medical Research Future Fund (MRFF)

Ovarian Cancer screening test | Path-to-market

Ovarian Cancer	• #8 cancer in women & **deadliest gynaecological cancer** • 314k new cases of ovarian cancer worldwide pa[1] • 0.25% of population has Hereditary Breast and Ovarian Cancer syndrome[2]
Unmet Medical Need	• **No approved test for early detection** of ovarian cancer in asymptomatic, average-risk women[3] • **Earlier and more accurate tests** required for screening high-risk women[3]
Market Potential	• **US$323m TAM** based on 538k tests pa @$600/test for OC high-risk screening twice yearly in US, EU5 and AU[4] • **US$32b TAM** based on 54.8m tests pa @$600/test for OC average-risk screening biennially in US, EU5 and AU[4]
Test & Data	• **Exosome multi-marker test** validated in a 465-sample retrospective case-control study with over **90% accuracy** for detection of stage I / II ovarian cancer[5] • Biomarker validation data from 500-sample independent set expected Dec-24
Intended Use	• **Screening** to detect ovarian cancer in asymptomatic, high-risk women
Go-to-Market Strategy	• IVD-MIA regulatory strategy (PMA process) with US FDA • **License** to large diagnostics / laboratory company

Development Path



***IVD-MIA** = In Vitro Diagnostic Multivariate Index Assay; **PMA** = Pre-Market Approval; 1. Cancer Today (iarc.fr); 2. Ovarian Cancer Diagnostics Market Size Worth US$ 1.8 Bn by (globenewswire.com) 3. HBOC Review 0.25% population (nih.gov); 4. See Appendix, OC Diagnostic Market Potential.; 5. University of Queensland OCRF-7 data (ASX: 1/4/22)*

THE UNIVERSITY OF QUEENSLAND AUSTRALIA

INOVIQ

Exosome Therapeutics| Next-gen cell-free therapy



- The therapeutic effects of **Cell Therapy** are mediated by exosomes interacting with host cells
- **Cell-Free Therapies** can be developed using exosomes isolated from allogenic MSC, T cells or NK cells grown *in vitro*
- INOVIQ is developing **weaponised exosomes** engineered to target and kill solid tumours
- CAR-exosomes inherit the **targeting and cytotoxic properties** of their parent cells to kill cancer
- Next-gen “off-the shelf” cell-free therapy for **solid tumours**
- Potential **safety, efficacy and cost advantages** over autologous CAR-T therapy

CAR = Chimeric Antigen Receptor; EV = Extracellular Vesicle or Exosome

CAR-Exosomes| Allogenic EV-based therapy with multiple advantages

Engineer immortalized CAR-cells → Establish Master Cell Bank → Activate and expand → Isolate EVs → In vitro efficacy → In vivo animal studies → IND → Phase I/II Clinical Trials

- ✓ **Improved efficacy** in solid tumours due to ability to infiltrate TME based on nano-size (10^{-9})
- ✓ **Multiple doses** and/or CAR-T follow-on or combination therapy
- ✓ Continuous manufacturing from immortalised cells enabling **off-the-shelf** (allogeneic) therapy for any patient
- ✓ Fast patient logistics and time-to-dose of **~1 week**
- ✓ **Reduced manufacturing** and supply chain costs
- ✓ **Lower treatment cost** per patient benefiting patients & healthcare system
- ✓ **Improved safety profile** due to reduced GvHD (immune rejection), CRS & secondary tumours as EVs don't replicate in the body



Clinical need & INOVIQ's CAR-EV targets

- cancers for which there are no targeted therapies (TNBC)
- cancers where Cell Therapy has limited access (glioblastoma)

GvHD = graft versus host disease; CRS = cytokine release syndrome

CAR-T-EVs| A promising alternative to cell-based therapies

CAR-EV generation, enrichment, EV characterisation and functional readout

- CAR-T cells targeting EGFR and HER2 were cultured and EVs isolated from cell-conditioned medium by ion-exchange chromatography (EXO-ACE™)
- EGFR targeting CAR-EVs reduced MCF-7 and K562 cell viability by 70% & 40%, respectively





T-Cells successfully transduced



CAR-EVs successfully isolated and enriched

[particle] increase ↑ 2-fold; protein ↓ 5- fold



EGFR targeting



HER2 targeting

Poster presentation: Asari et al., CAR-Extracellular Vesicles: A Promising Alternative to Cell-based Therapies. iPSC-Derived Cell Therapies symposium, Copenhagen Oct 2024

CAR-Exosome Therapy| Development path

- ✓Master cell banks established
- ✓**Cells engineered with CARs**

- ✓**High purity & yield of CAR-EVs**
- ✓Scalable EXO-ACE EV isolation process

- ✓**In vitro PoC** for CAR-T-EVs in BC cell line
- In vitro PoC for CAR-NK-EVs expected Dec-24

- In vivo studies commencing **1H25**
- Collaborations & contracts being established

CAR-Exosome in vitro proof of concept (PoC) established (ASX: 3/6/24)

INOVIQ

SubB2M Cancer Diagnostics

Improved cancer detection
and monitoring



neuraminic acid
(neu5Gc)

INOVIQ

SubB2M| Glycan-binding technology and scientific rationale

Aberrant glycosylation (production of sugars) is a hallmark of cancer

Neu5Gc is a sugar commonly found on cancer cells, but not healthy cells

SubB2M is an engineered protein that specifically binds neu5Gc

SubB2M is used in an **immunoassay format** to measure protein cancer biomarkers

Improves sensitivity and specificity for cancer detection (e.g. breast, ovarian, prostate, pancreatic & others)

Clinical applications for monitoring cancer treatment response and recurrence, general health assessment or high-risk screening



neu5Gc = the sialic acid, N-glycolylneuraminic acid

Breast Cancer monitoring test| Path-to-market

Breast Cancer	• **#1 cancer in women** • 2.3m new cases of breast cancer worldwide pa[1] • 7.8m survivors (5-year)[1]
Unmet Medical Need	• **Non-invasive, earlier and more accurate tests** required for monitoring breast cancer recurrence • **10-40%** of **breast cancers recur** within 5 years
Market Potential	• **US$4.3b** global breast cancer diagnostics market[2] • **US$668m TAM**[3]
Test & Data	• **NeuCA15-3 immunoassay** detects CA15-3 cancer marker bound to neu5Gc[4] to improve cancer specificity and sensitivity over existing CA15-3 test • **81% sensitivity and 93% specificity** for BC detection across all stages • Detects key BC subtypes incl. **HR+, HER2+ and TNBC**
Intended Use	• Aid in **monitoring** breast cancer treatment response and recurrence
Go-to-Market Strategy	• **LDT** to IVD regulatory strategy (510k / PMA process) with US FDA • **Partner** LDT with CLIA-accredited laboratory • **Licence** IVD to large diagnostics company

Development Path

Feasibility	Completed
Assay development	Completed
Analytical validation	Ongoing
Clinical validation	Completed
Monitoring study	Completed
Bead-based assay transfer	Underway
In-clinic study	Commence 1H25
LDT partner	2025

__510k__ = FDA clearance for Class II device; __CLIA__ = Clinical Laboratory Improvement Amendments (high-complexity tests) ; __IVD__ = In Vitro Diagnostic; __LDT__ = Laboratory Developed Test;
1. https://gco.iarc.fr/today/home; 2. Breast Cancer Diagnostics Market Size & Share Report 2030 (grandviewresearch.com); *3. Based on 4.5m tests pa @$150/test for BC monitoring in US, EU5 and AU; 4. __Neu5Gc__ = the sialic acid, N-glycolylneuraminic acid*

SubB2M Breast Cancer clinical data| Outperformed leading CA15-3 test

Clinical Validation Study by Stage (2023)[1]

Retrospective, case-control, **clinical validation study** (n=483) to evaluate breast cancer detection by stage

- ✓ **Detected all stages** of breast cancer with high accuracy (I - IV)
- ✓ Detected **common breast cancer types** (IDC and ILC)
- ✓ **Significantly outperformed a leading CA15-3 test** (Roche Elecsys® CA15-3 II)

Monitoring Study (2024)[2]

Retrospective, longitudinal, 2-arm **monitoring study** (n=277) to evaluate SubB2M CA15-3 test compared to Roche Elecsys® CA15-3 II (comparator)

- ✓ Detected main **breast cancer subtypes** (HR+, HER2+ and TNBC)[3] (n=159 pre-treatment samples)
- ✓ Established **equivalence for BC monitoring** (n=12 patients)
- ✓ Outperformed comparator identifying **19% more breast cancers**

SubB2M CA15-3 vs Leading Existing Test

Breast Cancer All Stages	SubB2M CA15-3	Roche Elecsys CA15-3 II
AUC	0.93	0.70
sensitivity	81%	37%
specificity	93%	88%
false negative rate	19%	63%
false positive rate	7%	12%
overall accuracy	87%	63%

Test Sensitivity by stage @95% Specificity



Breast cancer (n=241: I=75, II=72, 3=72, III=72, IV = 22) and healthy controls (n=242)

1. SubB2M/CA15-3 clinical validation results (ASX: 27/6/23) ; 2. Breast cancer monitoring study results (ASX: 22/2/24);
3. HR+ = Hormone Receptor, HER2+ = Human Epidermal growth factor Receptor 2 (HER2), Triple-Negative Breast Cancer (TNBC)

Summary & Catalysts



Summary| Developing better healthcare solutions

- Proprietary **exosome platform** with multiple research, diagnostic and therapeutic applications
- **Global distribution partner** for EXO-NET research tools to drive revenue growth
- Multiple **evaluations** underway for EXO-NET / NEURO-NET exosome isolation, biomarker discovery and diagnostics
- Clinically validated **SubB2M BC test** advancing to commercialisation
- **Pipeline** of advanced diagnostics and high-value therapeutics for cancer
- Leadership team with proven experience in **exosome science, development and commercialisation**

Financial information (ASX:IIQ)	
Ordinary shares[1]	111,526,702
Listed / Unlisted options[1]	9,378,913 / 7,824,889
52-week H/L[1]	A$0.82-0.435
Share price[1]	A$0.44
Market capitalisation[1]	A$49.0m
Cash at bank[2]	A$10.02m

Major shareholders (as at 15 November 2024)	
Merchant Funds Management	10.5%
Biotech Capital Management	6.4%
David Williams	4.5%

IIQ 12-month share price performance[1]



1. As at 15 Nov 2024; 2. Cash at 30 Sep 2024 (ASX: 31 Oct 2024)

Future milestones

	CY 2024	CY 2025
Exosome program	✓ **EXO-NET** Supply & Distribution Agreement with Promega ✓ **NEURO-NET validation data** in AD & PD ✓ **Exosome therapeutic** *in vitro* data ● **EXO-OC** test biomarker validation data ● **Exosome diagnostic** agreement	● Commence **exosome diagnostic** development for Neurodegenerative Disease ● Commence **EXO-OC test** clinical validation for ovarian cancer screening ● **Exosome therapeutic** *in vivo* data
SubB2M program	✓ **SubB2M breast cancer** monitoring study data	● **Laboratory partner** for SubB2M tests ● **SubB2M breast cancer** in-clinic monitoring study data ● First sales of **SubB2M breast cancer** monitoring test ● **SubB2M ovarian cancer** clinical validation study data

Future milestones are forward-looking and may change based on study results, funding, partnering and priorities

Contacts

Dr Leearne Hinch BVMS MBA
Chief Executive Officer
e. lhinch@inoviq.com

INOVIQ Ltd, 23 Normanby Road, Notting Hill, VIC 3168 Australia
p. +61 3 9548 7586 | e. info@inoviq.com | w. www.inoviq.com

Appendices



Products & pipeline| Multi-stage diagnostics and therapeutics portfolio

TECHNOLOGY	RESEARCH TOOLS	INDICATION	USE	DISCOVERY	VERIFICATION	VALIDATION	IN-MARKET
Exosomes	EXO-NET	Multiple	Pan-EV Capture				RUO
Exosomes	NEURO-NET	Neurology	Brain Derived-EV Capture			RUO	
Exosomes	TEXO-NET	Oncology	Tumour Derived-EV Capture	RUO			
	DIAGNOSTICS	**INDICATION**	**USE**	**DISCOVERY**	**ASSAY DEVELOPMENT**	**CLINICAL VALIDATION**	**IN-MARKET**
hTERT	hTERT ICC[1]	Bladder Cancer	Adjunct to Cytology				IVD-CLASS 1 USA
SubB2M	neuCA15-3	Breast Cancer	Monitoring			LDT	
SubB2M	neuCA125	Ovarian Cancer	Monitoring		LDT		
Exosomes	EXO-OC[2]	Ovarian Cancer	Screening	IVD			
	THERAPEUTICS	**INDICATION**	**USE**	**DISCOVERY**	**PRE-CLINICAL**	**CLINICAL**	**APPROVAL**
Exosomes	EEV-001	Breast Cancer	CAR-Exosome therapy				

***Exosome** = **EV** = Extracellular Vesicles ; **ICC** = Immunocytochemistry; **IVD** = In Vitro Diagnostic; **LDT** = Laboratory-Developed Test; **RUO** = Research Use Only;*
1. Adjunct to urine cytology to assist the detection of bladder cancer; 2. Umbrella Research & Option Agreement with University of Queensland

EXO-NET| Competitor comparison to other exosome isolation methods

Advantage \ Method	EXO-NET Immuno-affinity	Phospholipid-affinity	Charge	Size Exclusion	Precipitation	Ultra-centrifugation
Speed	+++	+++	+++	++	+++	+
Cost-Effectivness	+++	+++	++	++	++	++
Scalability	High	High	High	Med	Manual	Manual
Contaminants	Low	Med	Med	Med	High	High
Specificity	++++	++	++	++	+	+
Lab Compatibility	Yes	Yes	Yes	No	No	No
Customisable	Yes	No	No	No	No	No

Excellent — Poor

*Adapted from: Extracellular Vesicles and Their Emerging Roles as Cellular Messengers in Endocrinology: An Endocrine Society Scientific Statement. Carlos Salomon, Saumya Das, Uta Erdbrügger, Raghu Kalluri, Sai Kiang Lim, Jerrold M. Olefsky, **Gregory E. Rice**, Susmita Sahoo, W. Andy Tao, Pieter Vader, Qun Wang, and Alissa M. Weaver. **Endocrine Reviews, 2022, 43, 441–468***

INOVIQ